Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

The phosphatidylinositol-3-kinase (PI3K) pathway plays a crucial role in cell growth and survival and is activated in various cancers. Multiple components of the pathway are frequently targeted by ...

Cellular reprogramming is an intrinsic evolutionary trait to constantly promote adaptations that confer survival advantage.

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA highlighting the role of exosomal RNA (exRNA) in head and neck cancers (HNCs).

PI3K inhibitors. Alpelisib (Piqray) and inavolisib (Itovebi) block a type of PI3K protein in cancer cells and can be used to treat certain types of breast cancer with a PIK3CA gene mutation.

Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its ...

Phagocytosis is a fundamental mechanism used by the body to resist pathogens and restore physiological homeostasis. Herein, to identify small molecules with anti-inflammatory properties via ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...